Dyax (DYAX) leaps on successful tests

Dyax Corp. DYAX shares gained 51.8% to $25.43 after the company said a Phase Ib trial of its DX-2930 drug met safety goals and demonstrated statistically significant reductions in attack rates of hereditary angiodema, a rare disease. Share volume was 1.5 million, or five times its all-day average